Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/173668
Title: | Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study |
Author: | Meca Lallana, José E. Ayuso, Teresa Martínez Yélamos, Sergio Duran, Carmen Contreras Martín, Yessica Herrera Navarro, Nicolás Pérez Sempere, Angel Álvarez Cermeño, José C. Millán Pascual, Jorge Meca Lallana, Virginia Romero Sevilla, Raúl Ricart, Javier |
Keywords: | Esclerosi múltiple Inhibidors enzimàtics Multiple sclerosis Enzyme inhibitors |
Issue Date: | 1-May-2020 |
Publisher: | Karger AG |
Abstract: | Background: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). Methods: Multicenter, observational study, in which, information of 388 patients randomly selected and treated with FIN or NTZ in routine clinical practice was retrospectively collected with the main objective of comparing the annualized relapse rate (ARR) over the first year, after FIN or NTZ treatment initiation. Results: Mean ARR during the first year of treatment was 0.28 in FIN group and 0.12 in NTZ group (p = 0.0064); nevertheless, the difference between groups lost statistical significance when the propensity score analysis was performed. Time to disability -progression was similar in both treatment groups (12.3 +/- 6.7 months in FIN, and 12.8 +/- 0.1 months in NTZ; p = 0.4654). Treatment persistence after the first year of treatment was higher in patients treated with FIN (95%) than in those treated with NTZ (84%; p = 0.0014). Conclusions: After 12 months of treatment, both FIN and NTZ reduced the ARR, but ARR percent reduction was significantly higher with NTZ. Treatment persistence was higher in patients receiving FIN. |
Note: | Reproducció del document publicat a: https://doi.org/10.1159/000505778 |
It is part of: | European Neurology, 2020, vol. 83, p. 25-33 |
URI: | http://hdl.handle.net/2445/173668 |
Related resource: | https://doi.org/10.1159/000505778 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Meca-LallanaJ.pdf | 430 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License